WINSTON-SALEM, N.C., June 30, 2005 /PRNewswire/ - In a review of research to be published in the July issue of Trends In Pharmacological Sciences, Targacept compounds were reported to have a beneficial effect on cognition well after they were no longer present in the central nervous system. For example, in preclinical animal studies, Targacept's compounds TC-1827 and TC-1734 improved cognitive performance for up to 15 and 18 hours, respectively, though the compounds were appreciably metabolized and eliminated in less than an hour.
...
"Targacept's compounds act selectively on nicotinic acetylcholine receptor targets, and we anticipated this duration of effect based on extensive research of novel nicotinic compounds demonstrating sustained effects on cognition in animals," said Merouane Bencherif, M.D., Ph.D., Vice President, Preclinical Research.
Web site: http://www.targacept.com
http://www.pharmalive.com/News/index.cfm?articleid=252864&categoryid=15
No hay comentarios.:
Publicar un comentario